Imatinib plasma concentration – a new laboratory parameter for monitoring the treatment of Slovenian patients with chronic myeloid leukemia
Background: In past ten years imatinib (IM) has greatly improved the prognosis of patients with chronic myeloid leukemia (CML). However, 30 % of patients still fail to achieve treatment goals or cannot maintain them later. In the last three years, Imatinib plasma concentration (IPC) has been m...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Slovenian Medical Association
2011-03-01
|
| Series: | Zdravniški Vestnik |
| Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/425 |